Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
June 7, 2026
The hidden impact of veterinary care: new insights from a global survey of veterinarians
May 25, 2026
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
May 18, 2026
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
May 12, 2026
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
April 29, 2026